logo
Share SHARE
FONT-SIZE Plus   Neg

EU Approves Roche's Perjeta To Treat Metastatic Breast Cancer

Roche announced that it has received approval from European regulators for its perjeta drug to help treat breast cancer.

The approval comes from the European Medicines Agency and covers patients with previously untreated HER2-positive metastatic breast cancer. The drug is approved in combination with two other treatments - Herceptin and docetaxel - in adult patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The European approval comes after a late-stage trial showed that the combination of perjeta, Herceptin and chemotherapy provided patients with a median of 6.1 months longer without their disease worsening. It also provided a 34 percent reduction in the risk of death compared to Herceptin and chemotherapy alone.

The company said that perjeta is now approved in the EU, the U.S., and Switzerland for the treatment of people with this form of breast cancer. Further country approvals are anticipated during 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology. While reporting a wider loss for the first quarter, Sears Holdings Corp. said it has decided to "aggressively evaluate" all potential alternatives for its top brands - Kenmore, Craftsman and DieHard or KCD, and the Sears Home Services or SHS businesses. Sears has retained Citigroup Global Markets and LionTree Advisors to assist in its efforts.
comments powered by Disqus
Follow RTT